Introduction: The First Triple-Agonist Peptide
Retatrutide (LY3437943) represents a groundbreaking advancement in metabolic peptide research. As the first triple-agonist peptide targeting GIP, GLP-1, and glucagon receptors simultaneously, it has generated extraordinary scientific interest since its initial characterization.
This guide covers everything researchers need to know about retatrutide’s molecular design, mechanism, published findings, and laboratory handling.
Molecular Profile
- Development name: LY3437943
- Classification: Triple GIP/GLP-1/glucagon receptor agonist
- Amino acids: 39
- Structure: GIP-based backbone with engineered GLP-1 and glucagon receptor affinity
- Half-life: ~6 days in research models (supports weekly administration)
- Receptor targets: GIP receptor, GLP-1 receptor, Glucagon receptor
Why Triple Agonism Matters
Previous incretin-based peptide research has explored:
- Single agonists (e.g., semaglutide — GLP-1 only)
- Dual agonists (e.g., tirzepatide — GIP + GLP-1)
Retatrutide adds a third target — the glucagon receptor — which introduces an entirely new metabolic dimension. Glucagon receptor activation is associated with increased energy expenditure, hepatic lipid metabolism, and thermogenesis, creating a mechanism profile unlike any previous peptide.
Mechanism of Action: Three Pathways
1. GLP-1 Receptor Activation
Like semaglutide, retatrutide activates GLP-1 receptors to promote insulin secretion, suppress glucagon release, and slow gastric emptying. This pathway is the most well-characterized of the three.
2. GIP Receptor Activation
Similar to tirzepatide, retatrutide engages GIP receptors, which enhance insulin sensitivity and may improve lipid metabolism. The GIP component is thought to complement and amplify GLP-1 effects.
3. Glucagon Receptor Activation (Novel)
The glucagon receptor component is what makes retatrutide unique. Glucagon activation drives:
- Increased energy expenditure via thermogenesis
- Hepatic fat oxidation — breaking down liver fat stores
- Amino acid metabolism changes
- Ketogenesis stimulation
This triple combination creates a metabolic profile that simultaneously addresses glucose regulation, appetite signaling, and energy expenditure — three pillars that single or dual agonists can only partially engage.
Published Research Highlights
Phase 2 Clinical Trial (2023)
The landmark Phase 2 study published in the New England Journal of Medicine demonstrated retatrutide’s unprecedented research outcomes:
- Dose-dependent metabolic effects across all three receptor pathways
- Greater magnitude of body weight reduction than any previously studied single molecule
- Up to 24.2% mean body weight reduction at the highest dose over 48 weeks
- Significant improvements in glycemic parameters
- Notable effects on hepatic fat content
Ongoing Research Programs
Multiple Phase 3 trials are currently underway examining retatrutide’s effects across various metabolic conditions, including the TRIUMPH program studying long-term outcomes.
Retatrutide vs Other Metabolic Peptides
| Feature | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|
| Receptor Targets | GLP-1 | GIP + GLP-1 | GIP + GLP-1 + Glucagon |
| Generation | 1st gen incretin | 2nd gen (dual) | 3rd gen (triple) |
| Energy Expenditure | Minimal direct effect | Moderate | Strong (via glucagon) |
| Liver Fat Research | Some data | Promising data | Strong early data |
| Research Maturity | Fully characterized | Well characterized | Emerging (Phase 3) |
| Half-Life | ~7 days | ~5 days | ~6 days |
For a detailed comparison of semaglutide and tirzepatide specifically, see our Semaglutide vs Tirzepatide Guide.
Research Applications
Retatrutide is being studied across multiple research domains:
- Metabolic syndrome modeling — simultaneous glucose/lipid/weight pathway research
- Hepatic steatosis (fatty liver) research — glucagon-driven fat oxidation
- Energy expenditure studies — thermogenic effects via glucagon receptor
- Comparative incretin research — benchmarking triple vs dual vs single agonism
- Cardiovascular metabolic research — lipid profile and inflammatory marker effects
Storage and Handling
- Lyophilized: Store at -20°C, protect from light and moisture
- Reconstituted: 2-8°C, use within recommended stability window
- Reconstitution solvent: Bacteriostatic water
- Handling: Avoid repeated freeze-thaw, use aseptic technique
For complete protocols, see our Reconstitution Guide and Storage Guide.
Source Research-Grade Retatrutide
Proxiva Labs supplies retatrutide at >99.99% verified purity in 10mg and 20mg vials. Every batch includes third-party testing with full certificates of analysis.
Browse our complete research peptide catalog.
Disclaimer: All compounds are intended strictly for laboratory research and in-vitro use only. Not for human consumption.